Pangalos Menelas N 4

What Happened
Menelas Pangalos, a director of Biogen Inc. (BIIB), had three related transactions reported for 2026-06-09: an exercise/conversion of 2,370 derivative shares (acquired, $0.00), a grant/award of 1,505 restricted stock units (RSUs) ($0.00), and a disposition of 2,370 derivative shares (reported as derivative, $0.00). The filing reports $0 per share for these entries, so no cash price is shown in the record.

Key Details

• Transactions date: 2026-06-09; Form 4 filed: 2026-06-11 (filed within the normal 2-business-day window).
• Reported transactions: M (exercise/conversion of derivative) — 2,370 shares acquired; A (grant/award) — 1,505 RSUs acquired; M — 2,370 shares disposed (derivative). All reported at $0.00.
• Shares owned after the transactions: not specified in the filing.
• Footnotes:
  • F1: The RSUs (grant dated 6/9/2026) vest on the earlier of the next annual meeting or the one-year anniversary of the grant.
  • F2: The RSUs (from 6/17/2025) vest on the earlier of the next annual meeting or the one-year anniversary of that grant.
• No 10b5‑1 plan, tax‑withholding sale details, or cash proceeds are stated in the report.

Context

• Code M indicates an exercise or conversion of a derivative instrument (e.g., options or similar). The filing shows both an acquisition and a disposition of the same 2,370 derivative shares on the same date; the Form 4 does not state cash proceeds or explain whether this was a net/cashless settlement or a transfer for tax withholding.
• The award line (A) reflects new RSUs granted; vesting is time-based per the footnotes. These RSU awards are not the same as an open-market purchase and do not by themselves signal buy/sell intentions.